Related references
Note: Only part of the references are listed.Controversy and Debate: Questionable utility of the relative risk in clinical research: Paper 1: A call for change to practice
Suhail A. Doi et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2022)
A proposed framework to guide evidence synthesis practice for meta-analysis with zero-events studies
Chang Xu et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2021)
Safety and Efficacy of Revefenacin and Formoterol in Sequence and Combination via a Standard Jet Nebulizer in Patients with Chronic Obstructive Pulmonary Disease: A Phase 3b, Randomized, 42-Day Study
Thomas M. Siler et al.
CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION (2020)
Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials
Sanjay Sethi et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2020)
The methodological quality of dose-response meta-analyses needed substantial improvement: a cross-sectional survey and proposed recommendations
Chang Xu et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2019)
Revefenacin for the treatment of chronic obstructive pulmonary disease
Fuyuan Li et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials
James F. Donohue et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2019)
Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease
James F. Donohue et al.
RESPIRATORY MEDICINE (2019)
The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countries
D. M. G. Halpin et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2019)
Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized TreatmentOf COPD
James F. Donohue et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2019)
Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials
Gary T. Ferguson et al.
CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION (2019)
Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate
Donald A. Mahler et al.
CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION (2019)
Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)
James F. Donohue et al.
RESPIRATORY RESEARCH (2019)
Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies
Dean Quinn et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2018)
Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories
Kyle J. Foreman et al.
LANCET (2018)
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017
Gregory A. Roth et al.
LANCET (2018)
The robust error meta-regression method for dose-response meta-analysis
Chang Xu et al.
INTERNATIONAL JOURNAL OF EVIDENCE-BASED HEALTHCARE (2018)
Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy
Kesavan Suresh Babu et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2017)
A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease
Krishna K. Pudi et al.
RESPIRATORY RESEARCH (2017)
A review of nebulized drug delivery in COPD
Donald P. Tashkin
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2016)
Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients
Steven Kesten
International Journal of Chronic Obstructive Pulmonary Disease (2016)
Global and regional trends in COPD mortality, 1990-2010
Peter G. J. Burney et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends
Paolo Montuschi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
Mohsen Naghavi et al.
LANCET (2015)
Long-acting muscarinic antagonists
Andrea S. Melani
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2015)
Tiotropium versus placebo for chronic obstructive pulmonary disease
Charlotta Karner et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
The clinical and economic burden of chronic obstructive pulmonary disease in the USA
Anthony J. Guarascio et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2013)
In Vivo Pharmacological Characterization of TD-4208, a Novel Lung-Selective Inhaled Muscarinic Antagonist with Sustained Bronchoprotective Effect in Experimental Animal Models
M. T. Pulido-Rios et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Theo Vos et al.
LANCET (2012)
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
Rafael Lozano et al.
LANCET (2012)
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables
Gordon Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
A 4-year trial of tiotropium in chronic obstructive pulmonary disease
Donald P. Tashkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Chronic obstructive pulmonary disease: current burden and future projections
AD Lopez et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD
R Casaburi et al.
CHEST (2005)
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial
PS Burge et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Share Paper
